Daiichi Sankyo

This study tests whether adding the drug quizartinib to standard chemotherapy helps adults with a specific type of acute myeloid leukemia (AML) live longer. About 700 people aged 18 to 70 with newly diagnosed FLT3-ITD negative AML will receive either quizartinib or a placebo alon…

This early-stage study is testing a new drug called DS9051b in people with advanced adrenocortical carcinoma (a rare adrenal gland cancer) or metastatic castration-resistant prostate cancer. The main goals are to check the drug's safety and find the right dose. About 40 adults wi…

This study tests a new drug, ifinatamab deruxtecan (I-DXd), combined with standard treatments for people with extensive-stage small cell lung cancer (ES-SCLC) who have not had prior therapy. The goal is to see if the combination is safe and helps control the cancer longer. About …

This study tests whether a combination of two drugs (trastuzumab deruxtecan and pembrolizumab) works better than standard chemotherapy plus pembrolizumab for people with advanced non-small cell lung cancer that has high HER2 levels and low PD-L1. About 686 adults who have not had…

This study tests a new drug combination (datopotamab deruxtecan plus chemotherapy) against standard chemotherapy for people with advanced bladder cancer that has worsened after initial treatment. About 630 adults will participate to see if the new combo shrinks tumors or delays c…

This program offers the experimental drug I-DXd to adults with extensive-stage small cell lung cancer who have already tried at least two prior treatments, including platinum-based chemotherapy. It is for people who have no suitable treatment options and cannot join a clinical tr…

This study tests a new drug called DS3790a in people with blood cancers. The goal is to check its safety and how well it works, alone or with other treatments. About 420 adults will take part. The study is currently recruiting.

This early-stage trial tests a new drug called DS5361b, alone or with another drug (pembrolizumab), in adults with advanced solid tumors that haven't responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Abo…

This phase 3 trial tests whether a newer targeted drug (Enhertu) combined with chemotherapy and an immunotherapy (pembrolizumab) works better than the current standard treatment for advanced HER2-positive stomach or gastroesophageal junction cancer. About 726 adults who have not …

This early-stage study tests a new drug called DS3610a in about 70 adults with advanced or metastatic solid tumors that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the right dose. This is a first-in-human trial, so research…

This study offers continued treatment with certain cancer drugs for people with advanced or metastatic cancer who are already benefiting from them in earlier studies. The main goal is to monitor long-term safety, including side effects. About 50 adults will take part, and the stu…

This study is observing 800 Chinese adults with advanced HER2-positive or HER2-low breast cancer who are taking trastuzumab deruxtecan (T-DXd). Researchers will track how long the drug controls the cancer and note any side effects in real-world settings. The goal is to understand…

This study tests whether adding the drug Dato-DXd to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with advanced or spreading non-small cell lung cancer that has high levels of a protein called PD-L1. About 740 adults with this type of …

This study tests a new drug called ifinatamab deruxtecan (I-DXd) in people with advanced esophageal cancer that has worsened after standard chemotherapy and immunotherapy. About 510 participants will be randomly assigned to receive either I-DXd or another chemotherapy chosen by t…

This study tests a new drug called raludotatug deruxtecan (R-DXd) in people with advanced or metastatic solid tumors, including certain gynecological and genitourinary cancers. The goal is to see if the drug can shrink tumors or control the disease. About 200 adults who have alre…

This early-stage study tests a combination of two drugs (valemetostat tosylate and a DXd antibody-drug conjugate) in people with advanced solid tumors that have not responded to other treatments. The main goals are to check safety and find the right dose, and to see if the combin…

This study tests a new drug called R-DXd for people with ovarian, peritoneal, or fallopian tube cancer that has stopped responding to platinum chemotherapy. The drug is designed to target and kill cancer cells while sparing healthy ones. About 860 participants will be enrolled to…

This early-stage trial tests a new way to give the cancer drug trastuzumab deruxtecan (T-DXd) as a shot under the skin instead of through an IV. It aims to see if the shot is safe and works well in people with metastatic solid tumors that have spread. About 76 adults with advance…

This study tests two different doses of quizartinib as a maintenance treatment for adults with a specific type of acute myeloid leukemia (FLT3-ITD positive) who are in their first complete remission and have not had a stem cell transplant. The goal is to see which dose is safer a…

This phase 3 trial tests whether the targeted drug trastuzumab deruxtecan (T-DXd) works better than standard chemotherapy (with or without radiation) after surgery for HER2-positive endometrial cancer. About 710 adults with stage IIC or III disease will be enrolled. The main goal…

This study tests a drug called trastuzumab deruxtecan (T-DXd) in people with advanced breast cancer that has low levels of a protein called HER2 or no HER2 at all. The goal is to see how long the drug can control the cancer before another treatment is needed. About 250 participan…

This early-stage trial tests whether adding valemetostat to the standard drug darolutamide is safe and tolerable for men with metastatic castration-resistant prostate cancer (mCRPC), a type of prostate cancer that has spread and stopped responding to hormone therapy. About 60 adu…

This study tests an experimental drug called patritumab deruxtecan in people with advanced solid tumors that have spread or cannot be removed. The drug targets a protein called HER3 found on some cancer cells. About 740 adults with various cancers like lung, breast, or melanoma w…

This study tests a new drug, ifinatamab deruxtecan, in people with advanced solid tumors that have not been cured by other treatments. It is the first time this drug is being used in humans. The study has two parts: first, to find the safest dose, and second, to see how well the …

This study tests whether adding valemetostat to the standard immunotherapy pembrolizumab helps people with advanced non-small cell lung cancer that has high PD-L1 levels. About 137 adults who have not had prior treatment for advanced disease will take part. The goal is to see if …

This study tests a new drug called DS-3939a in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety and find the right dose, and to see if the drug can shrink tumors. About 540 adults will take part across multiple centers.

This study tests whether adding trastuzumab deruxtecan (T-DXd) to standard bevacizumab maintenance therapy helps women with advanced HER2-expressing ovarian cancer live longer without their cancer growing. About 582 participants will receive either the combination or bevacizumab …

This study tests an experimental drug called ifinatamab deruxtecan (I-DXd) in people whose cancer has come back or spread. It includes 13 different cancer types, such as endometrial, head and neck, pancreatic, and breast cancers. The goal is to see if the drug can shrink tumors a…

This study tests a new drug, ifinatamab deruxtecan, against standard treatments for people whose small cell lung cancer has returned. About 540 adults with advanced disease will be randomly assigned to receive the new drug or a doctor-chosen therapy. The goal is to see if the new…

This study follows up to 30 adults with tenosynovial giant cell tumor (TGCT) who had liver test abnormalities while taking TURALIO (pexidartinib). The goal is to track long-term risk of liver failure and understand the mechanism of liver injury through optional biopsies. Particip…

This study looks at how the drug quizartinib moves through the body in people with severe liver impairment compared to healthy volunteers. About 12 adults aged 18 to 75 will receive a single dose, and researchers will measure drug levels and check for side effects. The goal is to…